Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the launch of Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL). Glenmark's Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL) is ...

Glenmark Pharmaceuticals Inc. USA has launched Latanoprost Ophthalmic Solution, a 0.005% (0.05 mg/mL) ophthalmic solution. This product is bioequivalent and therapeutically equivalent to the reference ...

Glenmark Pharmaceuticals (NSE:GLEN) Inc., USA (Glenmark) has announced the launch of Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL), further strengthening its presence in the ophthalmic segment.

Glenmark Pharmaceuticals' subsidiary has introduced Latanoprost ophthalmic solution, a generic medication for glaucoma, in the US market. The product matches Upjohn US LLC's Xalatan Ophthalmic ...

Glenmark Pharmaceuticals said that US-based Glenmark Pharmaceuticals Inc. has launched Latanoprost Ophthalmic Solution. The aforementioned solution is bioequivalent and therapeutically equivalent to ...

(RTTNews) - Glenmark Pharmaceuticals Ltd. (GLENMARK.NS), Friday announced that it has introduced Latanoprost Ophthalmic Solution, 0.005 percent, a bioequivalent and therapeutically equivalent ...

Glenmark Pharmaceuticals Inc., USA announced today the launch of Latanoprost Ophthalmic Solution, 0.005 per cent, a generic version of Upjohn’s Xalatan. This marks the company’s fourth ...

Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the launch of latanoprost ophthalmic solution, 0.005% (0.05 mg/mL). Glenmark’s latanoprost ophthalmic solution, 0.005% (0.05 mg/mL) is ...